Close

Global Blood Therapeutics (GBT) Reaches Agreement with FDA on Design of Phase 3 GBT440 Trial in SCD

October 24, 2016 4:25 PM EDT Send to a Friend
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login